Publications

1. Rodriguez TA, Duvic M. Onset of alopecia areata after Epstein-Barr virus infectious mononucleosis. J Am Acad Dermatol 59(1):137-9, 7/2008.

2. Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome. Br J Dermatol 159(1):105-12, 7/2008.

3. Berthelot C, Rivera A, Duvic M. Skin directed therapy for mycosis fungoides: a review. J Drugs Dermatol 7(7):655-66, 7/2008.

4.  Vu BA, Duvic M. Central nervous system involvement in patients with mycosis fungoides and cutaneous large-cell transformation. J Am Acad Dermatol 59(2 Suppl 1):S16-22, 8/2008.

5.  Duvic M, Talpur R. Optimizing denileukin diftitox (Ontak) therapy. Future Oncol 4(4):457-69, 8/2008.

6.  Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R, Willemze R, Willemze R. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112(5):1600-9, 9/2008.

7.  Zhang C, Li B, Gaikwad AS, Haridas V, Xu Z, Gutterman JU, Duvic M. Avicin D Selectively Induces Apoptosis and Downregulates p-STAT-3, bcl-2, and Survivin in Cutaneous T-Cell Lymphoma Cells. J Invest Dermatol 128(11):2728-35, 11/2008. e-Pub 5/2008.

8.  Ni X, Richmond HM, Liao XM, Decker WK, Shiue LH, Shpall EJ, Duvic M. Induction of T-Cell responses against cutaneous T-Cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. J Invest Dermatol 128(11):2631-9, 11/2008. e-Pub 5/2008.

9.  Li C, Zhao H, Hu Z, Liu Z, Wang LE, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat 29(12):1443-1451, 12/2008. PMCID: PMC2937220.

10. Hicks LD, Duvic M. Wiskott-Aldrich syndrome and molluscum contagiosum: a therapeutic challenge after reaction to cidofovir. Int J Dermatol 47(12):1304-5, 12/2008.

11. Duvic M. EGFR inhibitor-associated acneiform folliculitis: assessment and management. Am J Clin Dermatol 9(5):285-94, 2008.

12. Talpur R, Cox K, Duvic M. Efficacy and safety of topical tazarotene: a review. Expert Opin Drug Metab Toxicol 5(2):195-210, 2/2009.

13. Sun G, Berthelot C, Li Y, Glass DA, George D, Pandya A, Kurzrock R, Duvic M. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol 60(2):231-5, 2/2009. e-Pub 11/2008.
14. Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 48(3):243-52, 3/2009.

15.  Chandra P, Plaza JA, Zuo Z, Diwan AH, Koeppen H, Duvic M, Medeiros LJ, Prieto VG. Clusterin expression correlates with stage and presence of large cells in mycosis fungoides. Am J Clin Pathol 131(4):511-5, 4/2009.

16.  Vidulich KA, Rady PL, He Q, Tyring SK, Duvic M. Detection of high-risk human papillomaviruses in verrucae of patients with mycosis fungoides and Sézary syndrome: a case series. Int J Dermatol 48(6):598-602, 6/2009.

17.  Kunishige JH, McDonald H, Alvarez G, Johnson M, Prieto V, Duvic M. Lymphomatoid papulosis and associated lymphomas: A retrospective case series of 84 patients. Clin Exp Dermatol 34(5):576-81, 7/2009. e-Pub 1/2009.

18.  Adeniran AJ, Prieto VG, Chon S, Duvic M, Diwan AH. Atypical histologic and immunohistochemical findings in melanocytic nevi after liquid nitrogen cryotherapy. J Am Acad Dermatol 61(2):341-5, 8/2009. e-Pub 4/2009.

19.  Terushkin V, Dusza SW, Mullani NA, Duvic M, Zouridakis G, Weinstock M, Drugge R, Prieto VG, Dhawan A, Terry C, Talpur R, Marghoob AA. Transillumination as a means to differentiate melanocytic lesions based on their vascularity. 
Arch Dermatol 145(9):1060-2, 9/2009.

20.  Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 15(19):6217-24, 10/2009. e-Pub 9/2009.

21.  Barahmani N, Schabath MB, Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol 61(4):581-91, 10/2009. e-Pub 7/2009.

22.  Talpur R, Vu J, Bassett R, Stevens V, Duvic M. Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. J Am Acad Dermatol 61(4):592.e1-9, 10/2009. e-Pub 8/2009.

23.  Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-Rodriguez C, Geskin LJ. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 9(6):412-415, 12/2009.

24.  Mukherjee N, Morrell DS, Duvic M, Stewart PW, Goldsmith LA. Attitudes of dermatologists in the southeastern United States regarding treatment of alopecia areata: a cross-sectional survey study. BMC Dermatol 9:11, 2009. PMCID: PMC2789708.

25.  Eubank KV, Nash J, Duvic M. Sweet syndrome associated with celiac disease. Am J Clin Dermatol 10(5):343-5, 2009.

26.  Khan O, Fotheringham S, Wood V, Stimson L, Zhang C, Pezzella F, Duvic M, Kerr DJ, La Thangue NB. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci USA 107(14):6532-7, 4/2010. e-Pub 3/2010. PMCID: PMC2851972.

27.  Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 28(11):1870-7, 4/2010. e-Pub 3/2010.

28.  Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, Acholonu S, Khouri I, Champlin R, Hosing C. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and sezary syndrome. J Clin Oncol 28(14):2365-72, 5/2010. e-Pub 3/2010.

29.  Duvic M. Improved understanding of peripheral T-cell lymphomas. Oncology (Williston Park) 24(7):587, 592-3, 6/2010.

30.  Patel P, Talpur R, Duvic M. Langerhans cell histiocytosis arising from a BCC: a case report and review of the literature. Cutis 85(6):295-300, 6/2010.

31.  Barahmani N, Lopez A, Babu D, Hernandez M, Donley SE, Duvic M. Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy. Clin Exp Dermatol 35(4):409-16, 6/2010. e-Pub 10/2009.

32.  Talpur R, Pozadzides JV, Bassett R, Daulat S, Stevens V, Duvic M. Topical bexarotene 1% gel for alopecia areata. J Clin Dermatol 1(1):1-9, 6/2010.

33.  Zhang C, Li B, Zhang X, Hazarika P, Aggarwal BB, Duvic M. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: Potential role for STAT-3 and NF-kappaB signaling. J Invest Dermatol 130(8):2110-9, 8/2010. e-Pub 4/2010.

34.  Cho-Vega JH, Tschen JA, Duvic M, Vega F. Early stage mycosis fungoides variants: Case-based review. Ann Diagn Pathol 14(5):369-85, 10/2010.

35.  Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28(29):4485-91, 10/2010. e-Pub 8/2010.

36.  Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B. A Phase II placebo controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol 63(6):984-90, 12/2010. e-Pub 10/2010.

37.  Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB. Chemoprevention of nonmelanoma skin cancer with celecoxib: A randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 102(24):1835-44, 12/2010. e-Pub 11/2010. PMCID: PMC3001966.

38.  Horwitz SM, Duvic M, Hsi ED. Clinical roundtable monograph. The management of aggressive T-cell lymphoma: a discussion on transformed mycosis fungoides. Clin Adv Hematol Oncol 8(12):1-15, 12/2010.

39.  Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 63(6):975-83, 12/2010. e-Pub 9/2010.

40.  Richmond HM, Duvic M, MacFarlane DF. Primary and metastatic malignant tumors of the scalp: an update. Am J Clin Dermatol 11(4):233-46, 2010.

41.  Wang LE, Huang YJ, Yin M, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer 47(1):107-15, 1/2011. e-Pub 7/2010. PMCID: PMC2987546.

42.  Bi MY, Curry JL, Christiano AM, Hordinsky MK, Norris DA, Price VH, Duvic M. The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 64(1):53-63, 1/2011. e-Pub 10/2010.

43.  Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64(2):352-404, 2/2011. e-Pub 12/2010.

44.  Chung JS, Shiue LH, Duvic M, Pandya A, Cruz PD, Ariizumi K. Sezary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-{beta} on the cell surface. Blood 117(12):3382-90, 3/2011. e-Pub 1/2011. PMCID: PMC3069677.

45.  Curry JL, Prieto VG, Jones DM, Vega F, Duvic M, Diwan AH. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome. J Cutan Pathol 38(3):295-7, 3/2011. e-Pub 11/2009.

46.  Ni X, Duvic M. Dendritic cells and cutaneous T-cell lymphomas. G Ital Dermatol Venereol 146(2):103-113, 4/2011.

47.  Talpur R, Demierre MF, Geskin L, Baron E, Pugliese S, Eubank K, Zic JA, Miller DR, Tharp M, Bohjanen K, Duvic M. Multicenter photopheresis intervention trial in early stage mycosis fungoides. Clin Lymphoma Myeloma Leuk 11(2):219-27, 4/2011. e-Pub 4/2011.

48.  Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC. Clinical end points and response criteria in mycosis fungoides and sezary syndrome: a consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European organization for research and treatment of cancer. J Clin Oncol 29(18):2598-607, 6/2011. e-Pub 5/2011. PMCID: PMC3422534.

49.  Martin SJ, Duvic M. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clin Lymphoma Myeloma Leuk 11(3):286-8, 6/2011. e-Pub 4/2011.

50.  Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A, Rook AH, Mark LA, Pinter-Brown L, Hamid O, Lin B, Bian Y, Boye M, Day JM, Rosen ST. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma 52(8):1474-80, 8/2011. e-Pub 6/2011.

51.  Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, Olsen E, Kim YH, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Cerroni L, Berti E, Horwitz S, Prince HM, Guitart J, Estrach T, Sanches JA, Duvic M, Ranki A, Dreno B, Ostheeren-Michaelis S, Knobler R, Wood G, Willemze R. European Organization for Research and Treatment of Cancer (EORTC), International Society of Cutaneous Lymphoma (ISCL) and United States Cutaneous Lymphoma Consortium (USCLC) consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 118(15):4024-35, 10/2011. e-Pub 8/2011. PMCID: PMC3204726.

52.  Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, Tsao H, Barbosa VH, Chuang TY, Duvic M, Ho VC, Sober AJ, Beutner KR, Bhushan R, Smith Begolka W. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 65(5):1032-47, 11/2011. e-Pub 8/2011.

53.  Duvic M. CD30+ neoplasms of the skin. Curr Hematol Malig Rep 6(4):245-50, 12/2011. e-Pub 8/2011.

54.  Williams VL, Torres-Cabala CA, Duvic M. Primary cutaneous, small to medium sized CD4+ pleomorphic T-cell lymphoma: A retrospective case series and review of the provisional cutaneous lymphoma category. Am J Clin Dermatol 12(6):389-401, 12/2011. e-Pub 8/2011.

55.  Rangwala S, Zhang C, Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med Chem 4(4):471-86, 3/2012.

56.  Liu H, Wei Q, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wang LE. Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res 22(2):169-75, 4/2012. e-Pub 12/2011. PMCID: PMC3296883.

57.  Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, Kurzrock R. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol 69(5):1117-26, 5/2012. e-Pub 12/2011.

58.  Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Blood 119(18):4115-22, 5/2012. e-Pub 3/2012.

59.  Goswami M, Duvic M, Dougherty A, Ni X. Increased Twist expression in advanced stage of mycosis fungoides and Sezary syndrome. J Cutan Pathol 39(5):500-7, 5/2012. PMCID: PMC3796850.

351.  Garcia-Uribe A, Zou J, Duvic M, Cho-Vega JH, Prieto VG, Wang LV. In vivo diagnosis of melanoma and non-melanoma skin cancer using oblique incidence diffuse reflectance spectrometry. Cancer Res 72(11):2738-45, 6/2012. e-Pub 4/2012. PMCID: PMC3367032.

60.  Talpur R, Duvic M. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas. Clin Lymphoma Myeloma Leukemia 12(3):180-185, 6/2012.

61.  Nicholson KM, Patel KP, Duvic M, Prieto VG, Tetzlaff MT. Bi-clonal, multifocal primary cutaneous marginal zone B-cell lymphoma: report of a case and review of the literature. J Cutan Pathol 39(9):866-71, 9/2012. e-Pub 7/2012.

62.  Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, Wei W, Duvic M. Long term outcomes of 1263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res 18(18):5051-60, 9/2012. e-Pub 7/2012. PMCID: PMC3857608.

63.  Holcomb M, Duvic M, Cutlan J. Erythema gyratum repens-like eruptions with large cell transformation in a patient with mycosis fungoides. Int J Dermatol 51(10):1231-3, 10/2012. e-Pub 7/2011.

64.  Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Photodermatol Photoimmunol Photomed 28(5):250-7, 10/2012.

65.  Martin SJ, Duvic M. Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome. Int J Dermatol 51(10):1195-8, 10/2012.

66.  Guitart J, Weisenburger DD, Subtil A, Kim E, Wood G, Duvic M, Olsen E, Junkins-Hopkins J, Rosen S, Sundram U, Ivan D, Selim MA, Pincus L, Deonizio JM, Kwasny M, Kim YH. Cutaneous γδ T-cell Lymphomas: A spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol 36(11):1656-1665, 11/2012.

67.  Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Straus DJ. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo. J Am Acad Dermatol 67(5):867-75, 11/2012. e-Pub 1/2012.

68.  Alexander LJ, Paravar T, Duvic M, Prieto V, Hymes SR. Annular plaques: An unusual manifestation of graft-versus-host disease. Dermatol Online J 18(6):4, 2012. e-Pub 6/2012.

69.  Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T-cell lymphomas: a retrospective analysis. Int J Dermatol 51:930-934, 2012.

70.  Prince HM, Martin AG, Olsen EA, Fivenson DP, Duvic M. Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and sézary syndrome. Leuk Lymphoma 54(1):69-75, 1/2013. e-Pub 9/2012. PMCID: PMC3523809.

71.  Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M, Lebbé C, Assaf C, Squier M, Williams D, Marshood M, Tai F, Prince HM. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. Eur J Cancer 49(2):386-94, 1/2013. e-Pub 9/2012.

72.  Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 149(1):25-32, 1/2013. PMCID: PMC3662469.

73.  Curry JL, Falchook GS, Hwu WJ, Torres-Cabala CA, Duvic M, Tetzlaff MT, Prieto VG. Changes in tumor morphology and cyclin dependent kinase inhibitor expression in metastatic melanoma treated with selective second generation BRAF inhibitor. Am J Dermatopathol 35(1):125-8, 2/2013. e-Pub 8/2012.

74.  Kim YH, Demierre MF, Kim EJ, Lerner A, Rook AH, Duvic M, Robak T, Samtsov A, McCulloch W, Chen SC, Waksman J, Nichols J, Whittaker S. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leuk Lymphoma 54(2):284-9, 2/2013. e-Pub 8/2012.

75.  Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and cutaneous T-cell lymphoma: Prospective analysis and case series. Cancer 119(4):825-31, 2/2013. e-Pub 9/2012.

76.  Duvic M, Martin AG, Olsen EA, Fivenson DP, Prince HM. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma 54(3):514-9, 3/2013. e-Pub 9/2012.

77.  Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. Clin Lymphoma Myeloma Leuk 13(4):377-84, 8/2013. e-Pub 6/2013.

78.  Shiue LH, Ni X, Prieto VG, Jorgensen JL, Curry JL, Goswami M, Sweeney SA, Duvic M. A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone. Int J Dermatol 52(9):1111-4, 9/2013. e-Pub 1/2012.

79.  Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E, Mitchell TJ, Cox M, Ferreira S, Liu P, Robson A, Calonje E, Stefanato CM, Wilkins B, Scarisbrick J, Wain EM, Child F, Morris S, Duvic M, Whittaker SJ. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer 49(13):2859-68, 9/2013. e-Pub 6/2013.

80.  Mendoza TR, Osei JS, Shi Q, Duvic M. Development of the alopecia areata symptom impact scale. J Investig Dermatol Symp Proc 16(1):S51-2, 12/2013.

82.  Shi Q, Duvic M, Osei JS, Hordinsky MK, Norris DA, Price VH, Amos CI, Christiano AM, Mendoza TR. Health-related quality of life (HRQoL) in alopecia areata patients-A secondary analysis of the National Alopecia Areata Registry data. J Investig Dermatol Symp Proc 16(1):S49-50, 12/2013.

83.  Duvic M, Christiano AM, Hordinsky MK, Norris DA, Price VH, Amos CI. The national alopecia areata registry-update. J Investig Dermatol Symp Proc 16(1):S53, 12/2013.

84.  Wang CM, Duvic M, Dabaja BS. Acral erosive mycosis fungoides: successful treatment with localized radiotherapy. BMJ Case Rep 2013, 2013. e-Pub 4/2013.

85.  Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, Kim CC, McCormack CJ, Myskowski PL, Spleiss O, Trunzer K, Su F, Nelson B, Nolop KB, Grippo JF, Lee RJ, Klimek MJ, Troy JL, Joe AK. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18(3):314-22, 2013. e-Pub 3/2013. PMCID: PMC3607529.

86.  Vin H, Ojeda SS, Ching G, Leung ML, Chitsazzadeh V, Dwyer DW, Adelmann CH, Restrepo M, Richards KN, Stewart LR, Du L, Ferguson SB, Chakravarti D, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Kim KB, Ciurea AM, Duvic M, Prieto VG, Ullrich SE, Dalby KN, Flores ER, Tsai KY. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife 2(0), 2013. e-Pub 11/2013. PMCID: PMC3814616.

87.  Straus DJ, Duvic M, Horwitz SM, Hymes K, Goy A, Hernandez-Ilizaliturri FJ, Feldman T, Wegner B, Myskowski PL. Final Results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Ann Oncol 25(1):206-10, 1/2014. e-Pub 11/2013.

88.  Aung PP, Climent F, Muzzafar T, Curry JL, Patel KP, Servitje O, Prieto VG, Duvic M, Jaffe ES, Torres-Cabala CA. Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases. J Cutan Pathol 41(1):51-7, 1/2014. e-Pub 11/2013.

89.  Vin H, Ching G, Ojeda SS, Adelmann CH, Chitsazzadeh V, Dwyer DW, Ma H, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Ciurea AM, Duvic M, Busaidy NL, Tannir NM, Tsai KY. Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Mol Cancer Ther 13(MCT-13-0561R):221-9, 1/2014. e-Pub 10/2013.

90.  Talpur R, Thompson A, Gangar P, Duvic M. Pralatrexate alone or in combination with Bexarotene: Long term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk. e-Pub 2/2014.

91.  Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM. Results of an open-label multicenter phase II trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. Blood 123(8):1159-66, 2/2014. e-Pub 12/2013.

92.  Dreno B, Urosevic-Maiwald M, Kim Y, Guitart J, Duvic M, Dereure O, Khammari A, Knol AC, Derbij A, Lusky M, Didillon I, Santoni AM, Acres B, Bataille V, Chenard MP, Bleuzen P, Limacher JM, Dummer R. TG1042 (Adenovirus-interferon-γ) in Primary Cutaneous B-cell Lymphomas: A Phase II Clinical Trial. PLoS One 9(2):e83670, 2/2014. e-Pub 2/2014. PMCID: PMC3933342.

93.  McQuitty E, Curry JL, Tetzlaff MT, Prieto VG, Duvic M, Torres-Cabala C. The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis. J Cutan Pathol 41(2):88-100, 2/2014. e-Pub 10/2013.
94.  Gera S, Dekmezian MS, Duvic M, Tschen JA, Vega F, Cho-Vega JH. Blastic plasmacytoid dendritic cell neoplasm: Evolving insights in an aggressive hematopoietic malignancy with a predilection of skin involvement. Am J Dermatopathol 36(3):244-51, 3/2014. e-Pub 11/2013.

95.  Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG. Dermatologic toxicities to targeted cancer therapy: Shared clinical and histologic adverse skin reactions. Int J Dermatol 53(3):376-84, 3/2014. e-Pub 7/2013.

96.  Wang LE, Li C, Xiong P, Gershenwald JE, Prieto VG, Duvic M, Lee JE, Grimm EA, Hsu TC, Wei Q. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res. e-Pub 6/2014.

97.  Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary Syndrome). Ann Oncol. e-Pub 6/2014.

98.  Kyvernitakis A, Duvic M, Mahale P, Torres HA. Interferon-Based Treatment for Patients with Mycosis Fungoides and Hepatitis C Virus Infection: A Case Series. Am J Clin Dermatol. e-Pub 6/2014.

99.  Applebaum DS, Daulat S, Duvic M. Multiple skin-colored papules with diffuse sclerosis. JAMA Dermatol. e-Pub 6/2014.

100. Venkatarajan S, Duvic M. Sezary syndrome: an overview of current and future treatment options. Expert Opinion on Orphan Drugs 2(9):1. e-Pub 6/2014.

101. Curry JL, Tetzlaff MT, Nicholson K, Duvic M, Kim KB, Tsai KY, Hwu WJ, Hong DS, Prieto VG, Torres-Cabala CA. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. Am J Dermatopathol 36(7):557-61, 7/2014.